1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6CE55BC34A1E9046B85257F3800771095
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-resourcing-successful-product-launch-staffing-allocations?opendocument
18
19opendocument
2098.81.24.230
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Resource Allocation

Resourcing a Successful Product Launch: Staffing Allocations

ID: 5398


Features:

12 Info Graphics

23 Data Graphics

800+ Metrics


Pages/Slides: 41


Published: Pre-2019


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Resourcing a Successful Product Launch: Staffing Allocations"

STUDY OVERVIEW

The biopharmaceutical launch landscape is characterized by growing competition in the market and tighter resources for pre-launch activities. Launching a new product in such a complex environment requires meticulous resource planning from the pre-launch phase to beyond market entry.

To help biopharma leaders develop competitive staffing targets for launch and pre-launch activities, Best Practices, LLC conducted benchmarking research that probed current staffing allocations across the key activities required for a successful drug launch.

In particular, the study benchmarks the FTE allocation for 12 key promotional, educational and market-access activities for the launch year and the three years preceding launch. The study also assesses the investment ratios by FTEs and outlines the success factors for launching a new pharmaceutical product.

Launch and brand leaders can use this research to compare their staffing levels for pre-launch and launch activities with current benchmark from industry peers.

This study includes staffing segments for: Peak revenue; drug type; launch year; product position; and oncology therapeutic area.

KEY TOPICS

  • Launch Staffing Allocations
  • Success Factors
  • Staffing Investment Ratios

SAMPLE KEY METRICS
  • Indicate the number of FTEs allocated for activities in 12 categories for the Launch Year and the three years preceding launch
  • Indicate the launch spend per FTE for products with projected peak revenue of less than $1 Billion


SAMPLE KEY FINDING
  • Among all the listed activities, sales field force activities receive highest staffing during launch year and launch year -1.
  • Sixty-four percent of the benchmark participants consider market access and reimbursement as the most important success factor in establishing and allocating new product launch budgets.


METHODOLOGY

This research engaged 34 marketing & commercial leaders from 27 leading pharmaceutical, biotech, and life sciences companies. Eleven study participants represent large pharma organizations, while the remaining benchmark class represent medium or small companies.

Industries Profiled:
Health Care; Pharmaceutical; Diagnostic; Medical Device; Manufacturing; Biotech; Consumer Products; Chemical


Companies Profiled:
Abbott; Cutanea Life Sciences; Abbvie; Pharmacyclics; Astellas; Sebela; Baxter Healthcare; Bayer; Boehringer Ingelheim; EMD Serono; Nektar Therapeutics; Grunenthal; Inspire Pharmaceuticals; Lundbeck; GlaxoSmithKline ; Novartis; Noven Therapeuticals; Novo Nordisk; Regeneron; Roche; Servier; Shire; Teva Pharmaceutical Industries Ltd; Zydus Cadila; Genentech; Lilly

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.